These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26272173)

  • 1. Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes.
    Herring R; Knight R; Shojaee-Moradie F; Johnsen S; Umpleby AM; Jackson N; Jones R; Dijk DJ; Russell-Jones DL
    Diabetes Obes Metab; 2015 Nov; 17(11):1100-3. PubMed ID: 26272173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of subcutaneous insulin detemir on glucose flux and lipolysis during hyperglycaemia in people with type 1 diabetes.
    Herring RA; Shojaee-Moradie F; Umpleby AM; Jones R; Jackson N; Russell-Jones DL
    Diabetes Obes Metab; 2015 May; 17(5):459-67. PubMed ID: 25580665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
    Smeeton F; Shojaee Moradie F; Jones RH; Westergaard L; Haahr H; Umpleby AM; Russell-Jones DL
    Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
    Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
    Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin: a randomized controlled crossover trial.
    van Golen LW; IJzerman RG; Huisman MC; Hensbergen JF; Hoogma RP; Drent ML; Lammertsma AA; Diamant M
    Diabetes Care; 2013 Dec; 36(12):4050-6. PubMed ID: 24130356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp.
    Hordern SV; Wright JE; Umpleby AM; Shojaee-Moradie F; Amiss J; Russell-Jones DL
    Diabetologia; 2005 Mar; 48(3):420-6. PubMed ID: 15729576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
    Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
    Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues and detemir in type 1 diabetic (T1D) pregnant women.
    Mello G; Biagioni S; Ottanelli S; Nardini C; Tredici Z; Serena C; Marchi L; Mecacci F
    J Matern Fetal Neonatal Med; 2015 Feb; 28(3):276-80. PubMed ID: 24724804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes.
    Zachariah S; Sheldon B; Shojaee-Moradie F; Jackson NC; Backhouse K; Johnsen S; Jones RH; Umpleby AM; Russell-Jones DL
    Diabetes Care; 2011 Jul; 34(7):1487-91. PubMed ID: 21593292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
    Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
    Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
    Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
    Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes.
    Kiess W; Raile K; Galler A; Kapellen T
    Diabetes Care; 2004 Oct; 27(10):2567-8. PubMed ID: 15451944
    [No Abstract]   [Full Text] [Related]  

  • 16. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
    Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K; Davies M
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
    Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.